PET scans to study hereditary amyloidosis
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 30 and 80 years old
- Be a carrier of a TTR mutation, have symptomatic hereditary ATTR cardiac amyloidosis, or be a non-carrier from the Dallas Heart Study
- Have completed the earlier study NCT05489549 at UT Southwestern (for carriers and symptomatic patients) or be part of the Dallas Heart Study (for controls)
- Have no other known cause of heart muscle disease or history of light-chain amyloidosis
- Have adequate kidney function and no history of type 1 heart attack
- Not be taking heparin or have certain thyroid issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
Hear when a new ATTR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.